全文获取类型
收费全文 | 1761407篇 |
免费 | 133489篇 |
国内免费 | 9796篇 |
专业分类
耳鼻咽喉 | 22375篇 |
儿科学 | 56337篇 |
妇产科学 | 47104篇 |
基础医学 | 248742篇 |
口腔科学 | 50235篇 |
临床医学 | 160969篇 |
内科学 | 341347篇 |
皮肤病学 | 39339篇 |
神经病学 | 134581篇 |
特种医学 | 66811篇 |
外国民族医学 | 303篇 |
外科学 | 264023篇 |
综合类 | 53301篇 |
一般理论 | 534篇 |
预防医学 | 127989篇 |
眼科学 | 42384篇 |
药学 | 131637篇 |
58篇 | |
中国医学 | 9084篇 |
肿瘤学 | 107539篇 |
出版年
2021年 | 14584篇 |
2019年 | 16290篇 |
2018年 | 22604篇 |
2017年 | 17926篇 |
2016年 | 18660篇 |
2015年 | 22696篇 |
2014年 | 30896篇 |
2013年 | 41852篇 |
2012年 | 58639篇 |
2011年 | 62109篇 |
2010年 | 36902篇 |
2009年 | 33845篇 |
2008年 | 55448篇 |
2007年 | 59013篇 |
2006年 | 59391篇 |
2005年 | 56870篇 |
2004年 | 53334篇 |
2003年 | 50484篇 |
2002年 | 48373篇 |
2001年 | 93302篇 |
2000年 | 95340篇 |
1999年 | 78867篇 |
1998年 | 20315篇 |
1997年 | 17758篇 |
1996年 | 17558篇 |
1995年 | 17652篇 |
1994年 | 16090篇 |
1993年 | 14581篇 |
1992年 | 57920篇 |
1991年 | 55790篇 |
1990年 | 53424篇 |
1989年 | 51135篇 |
1988年 | 46434篇 |
1987年 | 45202篇 |
1986年 | 42393篇 |
1985年 | 40130篇 |
1984年 | 29377篇 |
1983年 | 24895篇 |
1982年 | 13874篇 |
1979年 | 25489篇 |
1978年 | 17528篇 |
1977年 | 14849篇 |
1976年 | 13829篇 |
1975年 | 14513篇 |
1974年 | 17601篇 |
1973年 | 16907篇 |
1972年 | 15664篇 |
1971年 | 14433篇 |
1970年 | 13415篇 |
1969年 | 12504篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
2.
利用生物信息学技术初步探索芫根调控肠道免疫功能的分子生物学机制。方法 选择雄性SPF级BALB/c小鼠18只,随机分为3组,每组6只。SC1组小鼠每只每次灌胃芫根提取液150 μL,SC2组小鼠每只每次灌胃绞碎芫根原浆悬液150 μL,NC组小鼠每只每次灌胃生理盐水150 μL,连续7 d每日灌胃一次。分别取每组小鼠小肠组织样品提取RNA,总RNA的质检合格后,进行转录组测序。按GO功能和KEGG信号通路对差异表达基因聚类分析揭示差异表达高度富集的免疫相关通路。从免疫角度分析芫根灌胃小鼠小肠组织的基因表达变化情况。结果 转录组测序共检测到27733条 mRNA的表达,SC1组与NC组比较,显著差异表达基因1635个,其中上调差异表达基因1236个,下调差异表达基因399个;SC2组与NC组比较,显著差异表达基因2872个,其中上调差异表达基因2233个,下调差异表达基因639个(P<0.05)。按GO功能和KEGG信号通路聚类分析显示差异表达基因在白介素分泌、干扰素反应、T细胞受体信号通路及维生素和脂肪消化吸收等途径的富集度在两个芫根组中均居于前20位(P<0.01),肠黏膜趋化因子CCL20和巨噬细胞极化标志物CD274等免疫蛋白编码基因差异表达显著且同属于上述多个免疫通路。结论 芫根灌胃小鼠小肠的差异表达基因在白介素分泌、干扰素反应、T细胞受体信号通路、营养物质消化吸收等途径高度富集,提示芫根对肠道免疫系统及肠黏膜功能的调节,其中CD274的表达上调和CCL20的表达下调提示诱导M1型巨噬细胞极化和T细胞活化可能是芫根调控免疫和维护肠道正常结构功能的重要途径。 相似文献
3.
Espersen Caroline Modin Daniel Hoffmann Søren Hagemann Christoffer A. Hagemann Rikke A. Olsen Flemming J. Fritz-Hansen Thomas Platz Elke Møgelvang Rasmus Biering-Sørensen Tor 《The international journal of cardiovascular imaging》2022,38(1):131-140
The International Journal of Cardiovascular Imaging - Global longitudinal strain (GLS) has proven to be a powerful prognostic marker in various patient populations, but the prognostic value of... 相似文献
4.
5.
6.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
7.
8.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
9.
10.
S. M. White C. L. Shelton A. W. Gelb C. Lawson F. McGain J. Muret J. D. Sherman representing the World Federation of Societies of Anaesthesiologists Global Working Group on Environmental Sustainability in Anaesthesia 《Anaesthesia》2022,77(2):201-212
The Earth’s mean surface temperature is already approximately 1.1°C higher than pre-industrial levels. Exceeding a mean 1.5°C rise by 2050 will make global adaptation to the consequences of climate change less possible. To protect public health, anaesthesia providers need to reduce the contribution their practice makes to global warming. We convened a Working Group of 45 anaesthesia providers with a recognised interest in sustainability, and used a three-stage modified Delphi consensus process to agree on principles of environmentally sustainable anaesthesia that are achievable worldwide. The Working Group agreed on the following three important underlying statements: patient safety should not be compromised by sustainable anaesthetic practices; high-, middle- and low-income countries should support each other appropriately in delivering sustainable healthcare (including anaesthesia); and healthcare systems should be mandated to reduce their contribution to global warming. We set out seven fundamental principles to guide anaesthesia providers in the move to environmentally sustainable practice, including: choice of medications and equipment; minimising waste and overuse of resources; and addressing environmental sustainability in anaesthetists’ education, research, quality improvement and local healthcare leadership activities. These changes are achievable with minimal material resource and financial investment, and should undergo re-evaluation and updates as better evidence is published. This paper discusses each principle individually, and directs readers towards further important references. 相似文献